BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc., (NASDAQ:SCMP), an international biopharmaceutical company, today announced that, at its Board of Directors meeting, the Board received a report from management regarding AMITIZA® sales. In response, the Board of Directors expressed its disappointment with the level of U.S. AMITIZA sales being generated by Takeda Pharmaceuticals North America, a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. Sucampo is looking into ways to address the situation and is engaged in ongoing discussions with Takeda to explore ways to improve AMITIZA sales. In addition, Sucampo intends to exercise its rights to pursue a performance audit under its contract with Takeda.
